Especialistas de @FinlayInstituto y otros centros de @BioCubaFarma participan en reunión donde se analizan métodos de diagnóstico contra la #COVID19 de factura nacional que permiten garantizar soberanía tecnológica y la dependencia de importaciones. #CienciaCubana @DiazCanelB https://t.co/IWZkJ7QgNO
— Instituto Finlay (@FinlayInstituto) September 15, 2020
Following that premise, several specialists met on Tuesday from the Finlay Institute, Cuba’s Business Group of Biotechnology and Pharmaceutical Industries, as well as from the centers of Immunoassay and Genetic Engineering and Biotechnology.
In that sense, the Umelisa SARS COV-2 IgG system stands out, a diagnostic system created by the Immunoassay Center since May, which allows a greater number of people to be tested in order to detect and identify COVID-19 cases in a timely manner, isolate them and treat them.
Experts also focused on the progress of the analytical systems for different controls of Cuban ongoing vaccines.
(Taken from Prensa Latina)
